BRAF - B-Raf proto-oncogene, serine/threonine kinase Gene
Species: Sus scrofa
Gene Type: protein coding
Gene ID: 100514612
About BRAF
Primary_assembly 18: 8,957,991-9,132,553 forward strand.Sscrofa11.1:CM000829.5
This gene has 4 transcripts (splice variants), 220 orthologues and 23 paralogues. Ubiquitous expression in kidney (RPKM 3.3), lung (RPKM 3.1) and 8 other tissues.
BRAF Products (14)
| mRNA | Protein | Name |
|---|---|---|
| XM_005654267.3 | XP_005654324.1 | serine/threonine-protein kinase B-raf isoform X6 |
| XM_021078583.1 | XP_020934242.1 | serine/threonine-protein kinase B-raf isoform X1 |
| XM_021078584.1 | XP_020934243.1 | serine/threonine-protein kinase B-raf isoform X2 |
| XM_021078585.1 | XP_020934244.1 | serine/threonine-protein kinase B-raf isoform X3 |
| XM_021078587.1 | XP_020934246.1 | serine/threonine-protein kinase B-raf isoform X5 |
| XM_021078586.1 | XP_020934245.1 | serine/threonine-protein kinase B-raf isoform X4 |
| XM_021078588.1 | XP_020934247.1 | serine/threonine-protein kinase B-raf isoform X6 |
| XM_021078584.1 | XP_020934243.1 | serine/threonine-protein kinase B-raf isoform X2 |
| XM_021078585.1 | XP_020934244.1 | serine/threonine-protein kinase B-raf isoform X3 |
| XM_021078587.1 | XP_020934246.1 | serine/threonine-protein kinase B-raf isoform X5 |
| XM_021078586.1 | XP_020934245.1 | serine/threonine-protein kinase B-raf isoform X4 |
| XM_021078583.1 | XP_020934242.1 | serine/threonine-protein kinase B-raf isoform X1 |
| XM_021078588.1 | XP_020934247.1 | serine/threonine-protein kinase B-raf isoform X6 |
| XM_005654267.3 | XP_005654324.1 | serine/threonine-protein kinase B-raf isoform X6 |
BRAF Protein Structure
RBD_BRAF
RBD_BRAF: cd17134 (150 - 228)
C1_B-Raf
C1_B-Raf: cd20871 (226 - 285)
STKc_Raf
STKc_Raf: cd14062 (471 - 723)
- 0
- 200
- 400
- 600
- 776 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
serine/threonine-protein kinase B-raf |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(9)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-10201 | Sorafenib | 99.85% | Yes | |
| HY-14660 | Dabrafenib | 99.94% | Yes | |
| HY-12057 | Vemurafenib | 99.90% | Yes | |
| HY-15605 | Encorafenib | Inhibitor | 99.94% | Yes |
| HY-18652 | Avutometinib | Inhibitor | 99.43% | Unkown |
| HY-10201A | Sorafenib tosylate | 99.98% | Yes | |
| HY-10201S | Sorafenib-d3 | 99.57% | Unkown | |
| HY-10201R | Sorafenib (Standard) | 99.71% | Unkown | |
| HY-10201AR | Sorafenib tosylate (Standard) | / | Unkown |
Clinical Phase
Bioactive Molecules
(22)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-148439 | Daraxonrasib | Inhibitor | 99.96% | Phase 3 |
| HY-112089 | Naporafenib | Inhibitor | 99.92% | Phase 3 |
| HY-132844 | Tunlametinib | Inhibitor | 99.53% | Phase 3 |
| HY-10320 | Doramapimod | Inhibitor | 99.98% | Phase 2 |
| HY-109080 | Belvarafenib | Inhibitor | 98.97% | Phase 2 |
| HY-18972 | Plixorafenib | Inhibitor | 99.80% | Phase 2 |
| HY-114491 | Rineterkib | Inhibitor | 98.79% | Phase 2 |
| HY-111940 | LUT014 | 97.09% | Phase 2 | |
| HY-114491A | Rineterkib hydrochloride | Inhibitor | 99.81% | Phase 2 |
| HY-109080A | Belvarafenib TFA | Inhibitor | ≥99.0% | Phase 2 |
| HY-158115 | NST-628 | Inhibitor | 98.35% | Phase 1 |
| HY-51424 | PLX-4720 | Inhibitor | 99.90% | Phase 1 |
| HY-12558 | LY3009120 | 98.66% | Phase 1 | |
| HY-15200 | Agerafenib | Inhibitor | 99.78% | Phase 1 |
| HY-153341 | Tagarafdeg | Degrader | 99.41% | Phase 1 |
| HY-15610 | GDC-0623 | 98.74% | Phase 1 | |
| HY-18957 | Lifirafenib | Inhibitor | 98.01% | Phase 1 |
| HY-159795 | Claturafenib | Inhibitor | 99.95% | Phase 1 |
| HY-147405 | Tinlorafenib | Inhibitor | 98.21% | Phase 1 |
| HY-15199 | Agerafenib hydrochloride | Inhibitor | / | Phase 1 |
| HY-18957B | Lifirafenib maleate | Inhibitor | / | Phase 1 |
| HY-19343 | XL-281 | Inhibitor | / | Phase 1 |
Bioactive MoleculesInhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P991507 | SCT200 | Inhibitor | 99.09% | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(143)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-50846 | SCH772984 | Inhibitor | 99.83% | Unkown |
| HY-10966 | SB-590885 | Inhibitor | 99.77% | Unkown |
| HY-101494 | Temuterkib | Inhibitor | 99.93% | Unkown |
| HY-12661A | AMG PERK 44 | 99.67% | Unkown | |
| HY-50864 | GDC-0879 | Inhibitor | 99.49% | Unkown |
| HY-147268 | Exarafenib | Inhibitor | 99.68% | Unkown |
| HY-11004 | AZ 628 | 99.44% | Unkown | |
| HY-18832 | AWL-II-38.3 | Inhibitor | 99.68% | Unkown |
| HY-136420 | SJF-0628 | 99.90% | Unkown | |
| HY-15767 | TAK-632 | Inhibitor | 98.93% | Unkown |
| HY-W074340 | tert-Butyl 5-aminopentanoate | / | Unkown | |
| HY-Y1322 | Triphenyl phosphate | 99.67% | Unkown | |
| HY-137487 | PROTAC BRAF-V600E degrader-1 | Degrader | 98.04% | Unkown |
| HY-14177 | Raf inhibitor 1 | Inhibitor | 98.03% | Unkown |
| HY-202699 | SHOC2-RAS PPI-IN-1 | Inhibitor | 99.50% | Unkown |
| HY-17598 | Rafoxanide | 98.60% | Unkown | |
| HY-155736 | MAPK-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-181067 | IK-595 | Inhibitor | 98.55% | Unkown |
| HY-145120 | Mosperafenib | Inhibitor | 98.29% | Unkown |
| HY-111758 | PROTAC B-Raf degrader 1 | Inhibitor | 99.78% | Unkown |
| HY-N9330 | Broussoflavonol F | 98.11% | Unkown | |
| HY-12846 | CCT196969 | Inhibitor | 99.67% | Unkown |
| HY-100510 | RAF709 | Inhibitor | 99.92% | Unkown |
| HY-18997 | PLX7904 | Inhibitor | 98.72% | Unkown |
| HY-10247 | BRAF inhibitor | Inhibitor | 98.07% | Unkown |
| HY-136567 | TBAP-001 | Inhibitor | 98.97% | Unkown |
| HY-12787 | L-779450 | 98.75% | Unkown | |
| HY-107779 | BI-882370 | Inhibitor | 98.55% | Unkown |
| HY-77113 | B-Raf IN 11 | Inhibitor | 99.46% | Unkown |
| HY-12291 | HG6-64-1 | 99.32% | Unkown | |
| HY-149464 | ARN22089 | Inhibitor | 98.18% | Unkown |
| HY-P10438 | TAT-Braftide | Inhibitor | 99.52% | Unkown |
| HY-107415 | PLX7922 | Inhibitor | 98.68% | Unkown |
| HY-P10436 | Braftide | Inhibitor | 99.51% | Unkown |
| HY-148059 | Uplarafenib | Inhibitor | 99.63% | Unkown |
| HY-18227 | B-Raf IN 1 | Inhibitor | 99.94% | Unkown |
| HY-18507 | AD57 | Inhibitor | 98.27% | Unkown |
| HY-10201S2 | Sorafenib-13C,d3 | 98.35% | Unkown | |
| HY-117658 | GSK-114 | Inhibitor | 99.52% | Unkown |
| HY-153603 | B-Raf IN 15 | Inhibitor | 98.0% | Unkown |
| HY-142160 | GNE-9815 | Inhibitor | 98.94% | Unkown |
| HY-12847 | CCT241161 | 99.77% | Unkown | |
| HY-144269 | SHR902275 | Inhibitor | 99.80% | Unkown |
| HY-149380 | Vem-L-Cy5 | Inhibitor | 98.31% | Unkown |
| HY-P11706 | MS1 peptide | / | Unkown | |
| HY-15605S | Encorafenib-13C,d3 | Inhibitor | 98.14% | Unkown |
| HY-RS01588 | BRAF Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-117273 | AZ304 | Inhibitor | 99.77% | Unkown |
| HY-130617 | Pomalidomide-amido-C1-Br | / | Unkown | |
| HY-150639 | Everafenib | Inhibitor | / | Unkown |
| HY-15198 | KG5 | Inhibitor | 99.79% | Unkown |
| HY-164474 | DS03090629 | Inhibitor | / | Unkown |
| HY-179505 | OPN-9652 | Inhibitor | 98.84% | Unkown |
| HY-10966R | SB-590885 (Standard) | Inhibitor | 99.55% | Unkown |
| HY-164524 | SBI-0640726 | Inhibitor | / | Unkown |
| HY-10201S1 | Sorafenib-d4 | 99.9% | Unkown | |
| HY-108887 | Anticancer agent 124 | Inhibitor | / | Unkown |
| HY-11043 | PF-0419789 | Inhibitor | / | Unkown |
| HY-126298 | RAF mutant-IN-1 | Inhibitor | / | Unkown |
| HY-44237 | Pomalidomide-CO-C-NH2 | / | Unkown | |
| HY-10201S4 | Sorafenib-d3 tosylate | Inhibitor | / | Unkown |
| HY-103086 | INU-152 | Inhibitor | / | Unkown |
| HY-10966G | SB-590885 (GMP) | Inhibitor | / | Unkown |
| HY-115933 | EGFR/BRAF-IN-1 | Inhibitor | / | Unkown |
| HY-117707 | EBI-907 | Inhibitor | / | Unkown |
| HY-12057S | Vemurafenib-d5 | / | Unkown | |
| HY-12057S1 | Vemurafenib-d7 | / | Unkown | |
| HY-123799 | SB-699393 | Inhibitor | / | Unkown |
| HY-126180 | BAY-866 | Inhibitor | / | Unkown |
| HY-135216 | Antiproliferative agent-54 | Inhibitor | / | Unkown |
| HY-137488 | PROTAC BRAF-V600E degrader-2 | Inhibitor | / | Unkown |
| HY-13810 | PF-04880594 | Inhibitor | / | Unkown |
| HY-142820 | B-Raf IN 5 | Inhibitor | / | Unkown |
| HY-142830 | B-Raf IN 6 | Inhibitor | / | Unkown |
| HY-144271 | RAF-IN-1 | Inhibitor | / | Unkown |
| HY-146442 | BRAF V600E/CRAF-IN-1 | Inhibitor | / | Unkown |
| HY-146443 | BRAF V600E/CRAF-IN-2 | Inhibitor | / | Unkown |
| HY-146491 | VEGFR-2/BRAF-IN-1 | / | Unkown | |
| HY-146492 | VEGFR-2/BRAF-IN-2 | / | Unkown | |
| HY-147825 | EGFR/BRAFV600E-IN-1 | / | Unkown | |
| HY-147852 | B-Raf IN 7 | Inhibitor | / | Unkown |
| HY-147853 | B-Raf IN 8 | Inhibitor | / | Unkown |
| HY-147854 | B-Raf IN 9 | / | Unkown | |
| HY-149415 | Multi-kinase-IN-5 | Inhibitor | / | Unkown |
| HY-149517 | EGFR/BRAFV600E-IN-2 | / | Unkown | |
| HY-14979 | ML786 | Inhibitor | / | Unkown |
| HY-14979A | ML786 dihydrochloride | Inhibitor | / | Unkown |
| HY-150250 | B-Raf IN 13 | Inhibitor | / | Unkown |
| HY-153914 | B-Raf IN 14 | Inhibitor | / | Unkown |
| HY-155942 | B-Raf IN 19 | Inhibitor | / | Unkown |
| HY-156554 | Raf inhibitor 3 | Inhibitor | / | Unkown |
| HY-156590 | B-Raf IN 16 | Inhibitor | / | Unkown |
| HY-158027 | B-Raf IN 17 | Inhibitor | / | Unkown |
| HY-16063 | ARQ-736 | Inhibitor | / | Unkown |
| HY-162460 | ERK1/2 inhibitor 10 | Inhibitor | / | Unkown |
| HY-162873 | MEK/RAF-IN-1 | Inhibitor | / | Unkown |
| HY-164400 | SIJ1777 | / | Unkown | |
| HY-164428 | AE 51310 | Inhibitor | / | Unkown |
| HY-164492 | LSN3074753 | Inhibitor | / | Unkown |
| HY-168013 | KRASG12C IN-14 | Inhibitor | / | Unkown |
| HY-168125 | JNK-IN-18 | Inhibitor | / | Unkown |
| HY-168442 | KRAS inhibitor-40 | Inhibitor | / | Unkown |
| HY-168512 | BRAFV600E-IN-1 | Inhibitor | / | Unkown |
| HY-169869 | pan-Raf/RTK inhibitor 1 | Inhibitor | / | Unkown |
| HY-173164 | EGFR/BRAFV600E-IN-4 | / | Unkown | |
| HY-174274 | ERK2-IN-6 | Inhibitor | / | Unkown |
| HY-175435 | CST905 | Degrader | / | Unkown |
| HY-175726 | BRAF ligand-Linker Conjugate 1 | / | Unkown | |
| HY-175831 | BRAFV600E-IN-2 | Inhibitor | / | Unkown |
| HY-17598R | Rafoxanide (Standard) | / | Unkown | |
| HY-178995 | BRAFV600E-IN-3 | Inhibitor | / | Unkown |
| HY-179012 | CDC20/HSP90-IN-1 | / | Unkown | |
| HY-179098 | Multi-target kinase-IN-8 | / | Unkown | |
| HY-179559 | OPN-9643 | Inhibitor | / | Unkown |
| HY-180154 | EGFR/BRAFV600E-IN-6 | / | Unkown | |
| HY-180161 | B-Raf-IN-20 | Inhibitor | / | Unkown |
| HY-180419 | SF-3-030 | / | Unkown | |
| HY-181061 | COX/5-LO-IN-2 | / | Unkown | |
| HY-181130 | Anticancer agent 299 | / | Unkown | |
| HY-181131 | Anticancer agent 300 | / | Unkown | |
| HY-181913 | KRAS G12C-IN-76 | Inhibitor | / | Unkown |
| HY-181978 | GIT1-IN-1 | / | Unkown | |
| HY-182763 | EGFR/BRAFV600E-IN-7 | / | Unkown | |
| HY-18318 | Takeda-6D | Inhibitor | 99.41% | Unkown |
| HY-183674 | MEK-IN-10 | / | Unkown | |
| HY-184546 | BRAFV600E ligand-1 | Ligand | / | Unkown |
| HY-184581 | Pomalidomide-5-C4-acid | / | Unkown | |
| HY-18507A | AD57 hydrochloride | Inhibitor | / | Unkown |
| HY-18652A | Avutometinib potassium | Inhibitor | / | Unkown |
| HY-E70649 | BRAF V600E Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-N13841 | 2,4,3',4',6'-Penta-O-(3-methylbutanoyl)sucrose | / | Unkown | |
| HY-RS01589 | Braf Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS01590 | Braf Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-120676 | B-Raf IN 18 | Inhibitor | / | Unkown |
| HY-14177A | Raf inhibitor 1 dihydrochloride | Inhibitor | 99.29% | Unkown |
| HY-164529 | SJ-C1044 | Inhibitor | 98.63% | Unkown |
| HY-164530 | SKLB646 | Inhibitor | / | Unkown |
| HY-177946 | RAF-IN-4 | Inhibitor | / | Unkown |
| HY-180329 | CG 858-Neg | / | Unkown | |
| HY-186223 | Enzyme modulator-1 | Modulator | / | Unkown |
| HY-18817 | AFG210 | Inhibitor | / | Unkown |
| HY-41747 | BRAF ligand-1 | Ligand | / | Unkown |
| HY-51424S | PLX-4720-d7 | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service